Efficacy and safety of olmesartan medoxomil alone and in combination with hydrochlorothiazide

Expert Review of Cardiovascular Therapy

Volumn 7, Issue 3, 2009, Pages 229-239

  Punzi, Henry A ^a  

^a TEXAS WOMAN'S UNIVERSITY   (United States)

Author keywords

Combination; Efficacy; Hydrochlorothiazide; Hypertension; Medoxomil; Olmesartan; Safety

Indexed keywords

ALMETEC CO; AMLODIPINE; AMLODIPINE BESYLATE; AMLODIPINE PLUS BENAZEPRIL; ANTIHYPERTENSIVE AGENT; ATENOLOL; BENETOR COMP; BENETOR PLUS; BENICAR HCT; CANDESARTAN HEXETIL; CAPTOPRIL; CARDOSAL PLUS; CO OLMETEC; CO TENSIOL; FELODIPINE; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS LOSARTAN; HYDROCHLOROTHIAZIDE PLUS OLMESARTAN; IRBESARTAN; LOSARTAN; NITRENDIPINE; OLMEGAN; OLMESARTAN; OLMETEC D; OLMETEC PLUS; OMESAR PLUS; PLACEBO; TELMISARTAN; UNCLASSIFIED DRUG; VALSARTAN; IMIDAZOLE DERIVATIVE; TETRAZOLE DERIVATIVE;

ARTICLE; CLINICAL TRIAL; DIABETES MELLITUS; DIZZINESS; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; ESSENTIAL HYPERTENSION; GLUCOSE BLOOD LEVEL; HALF LIFE TIME; HUMAN; HYPERTENSION; HYPERURICEMIA; HYPOKALEMIA; HYPONATREMIA; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NONHUMAN; PHARMACODYNAMICS; PLASMA CONCENTRATION-TIME CURVE; PLASMA PROTEIN BINDING; POTASSIUM BLOOD LEVEL; SIDE EFFECT; SYSTOLIC HYPERTENSION; UPPER RESPIRATORY TRACT INFECTION; URIC ACID BLOOD LEVEL; ANIMAL; BLOOD PRESSURE; DRUG COMBINATION; DRUG EFFECT; PRACTICE GUIDELINE; REVIEW;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CLINICAL TRIALS AS TOPIC; DRUG COMBINATIONS; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; IMIDAZOLES; PRACTICE GUIDELINES AS TOPIC; TETRAZOLES;

EID: 66149190955     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.7.3.229     Document Type: Article

References (57)

1. Rosamond W, Flegal K, Furie K et al. Heart disease and stroke statistics - 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 117(4), e25-e146 (2008).
2. Chobanian AV, Bakris GL, Black HR et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42(6), 1206-1252 (2003).
3. Kjeldsen SE, Os I, Hoieggen A et al. Fixed-dose combinations in the management of hypertension: defining the place of angiotensin receptor antagonists and hydrochlorothiazide. Am. J. Cardiovasc. Drugs 5(1), 17-22 (2005).
4. Ong KL, Cheung BM, Man YB, Lau CP, Lam KS. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension 49(1), 69-75 (2007).
5. Hyman DJ, Pavlik VN. Self-reported hypertension treatment practices among primary care physicians: blood pressure thresholds, drug choices, and the role of guidelines and evidence-based medicine. Arch. Intern. Med. 160(15), 2281-2286 (2000).
6. Cushman WC, Ford CE, Cutler JA et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J. Clin. Hypertens. (Greenwich) 4(6), 393-404 (2002).
7. Hansson L, Zanchetti A, Carruthers SG et al.; the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 351(9118), 1755-1762 (1998).
8. Dahlof B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359(9311), 995-1003 (2002).
9. Mizuno M, Sada T, Ikeda M et al. Pharmacology of CS-866, a novel nonpeptide angiotensin II receptor antagonist. Eur. J. Pharmacol. 285(2), 181-188 (1995).
10. Kim S, Izumi Y, Izumiya Y et al. Beneficial effects of combined blockade of ACE and ATI receptor on intimal hyperplasia in balloon-injured rat artery. Arterioscler. Thromb. Vasc. Biol. 22(8), 1299-1304 (2002).
11. 1, receptor antagonist. J. Hypertens. Suppl. 19(1), S3-S14 (2001).
12. 1 receptor blocker on neointima formation. Hypertension 40(4), 451-457 (2002).
13. Miyazaki M, Takai S. Anti-atherosclerotic efficacy of olmesartan. J. Hum. Hypertens. 16(Suppl. 2), S7-S12 (2002).
14. Mukai Y, Shimokawa H, Higashi M et al. Inhibition of renin-angiotensin system ameliorates endothelial dysfunction associated with aging in rats. Arterioscler. Thromb. Vasc. Biol. 22(9), 1445-1450 (2002).
15. Takai S, Jin D, Sakaguchi M, Muramatsu M, Miyazaki M. The regressive effect of an angiotensin II receptor blocker on formed fatty streaks in monkeys fed a high-cholesterol diet. J. Hypertens. 23(10), 1879-1886 (2005).
16. Takai S, Kim S, Sakonjo H, Miyazaki M. Mechanisms of angiotensin II type 1 receptor blocker for anti-atherosclerotic effect in monkeys fed a high-cholesterol diet. J. Hypertens. 21(2), 361-369 (2003).
17. Jia N, Okamoto H, Shimizu T et al. A newly developed angiotensin II type 1 receptor antagonist, CS866, promotes regression of cardiac hypertrophy by reducing integrin β expression. Hypertens. Res. 26(9), 737-742 (2003).
18. Nakamura Y, Yoshiyama M, Omura T et al. Beneficial effects of combination of ACE inhibitor and angiotensin II type 1 receptor blocker on cardiac remodeling in rat myocardial infarction. Cardiovasc. Res. 57(1), 48-54 (2003).
19. Takemoto M, Egashira K, Tomita H et al. Chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade: effects on cardiovascular remodeling in rats induced by the long-term blockade of nitric oxide synthesis. Hypertension 30(6), 1621-1627 (1997).
20. Taniyama Y, Morishita R, Nakagami H et al. Potential contribution of a novel antifibrotic factor, hepatocyte growth factor, to prevention of myocardial fibrosis by angiotensin II blockade in cardiomyopathic hamsters. Circulation 102(2), 246-252 (2000).
21. Mizuno M, Sada T, Kato M, Koike H. Renoprotective effects of blockade of angiotensin II ATI receptors in an animal model of Type 2 diabetes. Hypertens. Res. 25(2), 271-278 (2002).
22. Nangaku M, Miyata T, Sada T et al. Anti-hypertensive agents inhibit in vivo the formation of advanced glycation end products and improve renal damage in a Type 2 diabetic nephropathy rat model. J. Am. Soc. Nephrol. 14(5), 1212-1222 (2003).
23. Yoshida K, Perich R, Casley DJ, Johnston CI. Hypotensive effect of ZD7155, an angiotensin II receptor antagonist, parallels receptor occupancy in two-kidney, one-clip Goldblatt hypertensive rats. J. Hypertens. 16(5), 645-655 (1998).
24. - cotransporter: a new model for ions and diuretics interaction, Am. J. Physiol Renal Physiol. 279(1), F161-F169 (2000).
25. Meredith PA. Angiotensin II receptor antagonists alone and combined with hydrochlorothiazide: potential benefits beyond the antihypertensive effect. Am. J. Cardiovasc. Drugs 5(3), 171-183 (2005).
26. Kobayashi N, Fujimori I, Watanabe M, Ikeda T. Real-time monitoring of metabolic reactions by microdialysis in combination with tandem mass spectrometry: hydrolysis of CS-866 in vitro in human and rat plasma, livers, and small intestines. Anal. Biochem. 287(2), 272-278 (2000).
27. Laeis P, Puchler K, Kirch W. The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction. J. Hypertens. Suppl. 19(1), S21-S32 (2001).
28. Yanagisawa H, Amemiya Y, Kanazaki T et al. Nonpeptide angiotensin II receptor antagonists: synthesis, biological activities, and structure-activity relationships of imidazole-5-carboxylic acids bearing alkyl, alkenyl, and hydroxyalkyl substituents at the 4-position and their related compounds. J. Med. Chem. 39(1), 323-338 (1996).
29. 1, receptor. Br. J. Pharmacol. 151(7), 952-962 (2007).
30. Benicar HCT® (olmesartan medoxomil-hydrochlorothiazide), prescribing information. Daiichi Sankyo, Inc., NJ, USA (2007).
31. Huber M, Bolbrinker J, Kreutz R. Pharmacokinetics and safety of olmesartan medoxomil in combination with glibenclamide in healthy volunteers. Clin. Exp. Hypertens), 631-643 (2006).
32. Kreutz R, Bolbrinker J, Huber M. Pharmacokinetics of olmesartan medoxomil plus hydrochlorothiazide combination in healthy subjects. Clin. Drug Investig. 26(1), 29-34 (2006).
33. Ball KJ, Williams PA, Stumpe KO. Relative efficacy of an angiotensin II antagonist compared with other antihypertensive agents. Olmesartan medoxomil versus antihypertensives. J. Hypertens. 19 (Suppl. I), S49-S56 (2001).
34. Oparil S, Williams D, Chrysant SG, Marbury TC, Neutel J. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J. Clin. Hypertens. (Greenwich) 3(5), 283-291, 318 (2001).
35. Stumpe KO, Ludwig M. Antihypertensive efficacy of olmesartan compared with other antihypertensive drugs. J. Hum. Hypertens. 16(Suppl. 2), S24-S28 (2002).
36. Chrysant SG, Marbury TC, Robinson TD. Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension. J. Hum. Hypertens. 17(6), 425-432 (2003).
37. Giles TD, Oparil S, Silfani TN, Wang A, Walker JF. Comparison of increasing doses of olmesartan medoxomil, losartan potassium, and valsartan in patients with essential hypertension. J. Clin. Hypertens. (Greenwich) 9(3), 187-195 (2007).
38. Brunner HR, Stumpe KO, Januszewicz A. Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil assessed by 24-hour ambulatory blood pressure monitoring in patients with essential hypertension. Clin. Drug Investig. 23(7), 419-430 (2003).
39. Giles TD, Robinson TD. Effects of olmesartan medoxomil on systolic blood pressure and pulse pressure in the management of hypertension. Am. J. Hypertens. 17(8), 690-695 (2004).
40. Brunner HR, Arakawa K. Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil in achieving 24-hour blood pressure reductions and ambulatory blood pressure goals. Clin. Drug Investig. 26(4), 185-193 (2006).
41. Chrysant SG, Weber MA, Wang AC, Hinman DJ. Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide. Am. J. Hypertens. 17(3), 252-259 (2004).
42. Chrysant S, Dubiel R, Chavanu K. Secondary analysis of the distribution of blood pressure (BP) reductions in patients (pts) receiving olmesartan medoxomil (OLM) and hydrochlorothiazide (HCTZ) in a factorial-design study [abstract]. J. Clin. Hypertens. (Greenwich) 9(Suppl. A), A155 (2007).
43. Chrysant S, Dubiel R, Chavanu K. Correlation between blood pressure (BP) reduction and baseline BP in patients (pts) receiving olmesartan medoxomil (OLM) and/or hydrochlorothiazide (HCTZ) in a factorial design study [abstract]. J. Clin. Hypertens. (Greenwich) 9(Suppl. A,5), A156 (2007).
44. Sellin L, Stegbauer J, Laeis P, Rump LC. Adding hydrochlorothiazide to olmesartan dose dependently improves 24-h blood pressure and response rates in mild-to-moderate hypertension. J. Hypertens. 23(11), 2083-2092 (2005).
45. Barrios V, Boccanelli A, Ewald S et al. Efficacy and tolerability of olmesartan medoxomil in patients with mild to moderate essential hypertension: the OLMEBEST Study. Clin. Drug Investig. 27(8), 545-558 (2007).
46. Izzo JL Jr, Neutel JM, Silfani T, Dubiel R, Walker F. Efficacy and safety of treating stage 2 systolic hypertension with olmesartan and olmesartan/HCTZ: results of an open-label titration study. J. Clin. Hypertens. (Greenwich) 9(1), 36-44 (2007).
47. Izzo JL Jr, Neutel JM, Silfani T, Dubiel R, Walker F. Titration of HCTZ to 50 mg daily in individuals with stage 2 systolic hypertension pretreated with an angiotensin receptor blocker. J. Clin. Hypertens. (Greenwich) 9(1), 45-48 (2007).
48. Kereiakes DJ, Neutel JM, Punzi HA et al. Efficacy and safety of olmesartan medoxomil and hydrochlorothiazide compared with benazepril and amlodipine besylate. Am. J. Cardiovasc. Drugs 7(5), 361-372 (2007).
49. Neutel JM, Smith DH, Silfani TN, Lee Y, Weber MA. Effects of a structured treatment algorithm on blood pressure goal rates in both stage 1 and stage 2 hypertension. J. Hum. Hypertens. 20(4), 255-262 (2006).
50. Neutel JM, Smith DH, Weber MA, Wang AC, Masonson HN. Use of an olmesartan medoxomil-based treatment algorithm for hypertension control. J. Clin. Hypertens. (Greenwich) 6(4), 168-174 (2004).
51. Rump LC, Ambrosioni E, Burnier M, Horl W, Rabelink AJ. Initial combination therapy with olmesartan/hydrochlorothiazide in moderate-to-severe hypertension. J. Hum. Hypertens. 20(4), 299-301 (2006).
52. Mallion JM, Heagerty A, Laeis P. Systolic blood pressure reduction with olmesartan medoxomil versus nitrendipine in elderly patients with isolated systolic hypertension. J. Hypertens. 25(10), 2168-2177 (2007).
53. Neutel JM. Clinical studies of CS-866, the newest angiotensin II receptor antagonist. Am. J. Cardiol, 87(3A), 37C-43C (2001).
54. Reyes AJ. Diuretics in the therapy of hypertension. J. Hum. Hypertens. 16(Suppl. 1), S78-S83 (2002).
55. Sweetman SC. Martindale: the Complete Drug Reference. Pharmaceutical Press, London, UK (2005).
56. Punzi HA, Punzi CF. Metabolic issues in the Antihypertensive and Lipid-Lowering Heart Attack Trial Study. Curr. Hypertens. Rep. 6(2), 106-110 (2004).
57. Julius S, Kjeldsen SE, Weber M et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363(9426), 2022-2031 (2004).